Alfredsson G, Härnryd C, Wiesel F A
Psychopharmacology (Berl). 1985;85(1):8-13. doi: 10.1007/BF00427315.
Schizophrenic patients were treated with fixed doses of sulpiride (800 mg/day) or chlorpromazine (CPZ) (400 mg/day) during a period of 8 weeks using a double-blind design. There were 25 patients in each group and all of them fulfilled the Research Diagnostic Criteria (RDC) for schizophrenia. Autistic and psychotic symptoms were rated with subscales developed from the Comprehensive Psychopathological Rating Scale (CPRS). Autistic symptoms were also rated with a subscale of the Nurse's Observation Scale for Inpatient Evaluation (NOSIE). Sulpiride was superior to CPZ in reducing the autistic symptoms. Patients with low concentrations of sulpiride in serum had a better recovery rate from autistic symptoms than those with high concentrations. Both drugs reduced positive psychotic symptoms to the same degree.
采用双盲设计,在8周的时间里,对精神分裂症患者使用固定剂量的舒必利(800毫克/天)或氯丙嗪(CPZ)(400毫克/天)进行治疗。每组有25名患者,他们均符合精神分裂症的研究诊断标准(RDC)。使用从综合精神病理学评定量表(CPRS)衍生出的分量表对自闭症和精神病症状进行评分。还使用住院患者评估护士观察量表(NOSIE)的一个分量表对自闭症症状进行评分。在减轻自闭症症状方面,舒必利优于氯丙嗪。血清中舒必利浓度低的患者自闭症症状的恢复率高于浓度高的患者。两种药物在减轻阳性精神病症状方面程度相同。